Asia Green Biotechnology Corp. announced that it has entered an agreement with Pathway Rx Inc. and Swysh Inc. pursuant to which AGB has expanded its commitment to assist in the develop and commercialize the Cannabis sativa varieties to which Pathway Rx Inc. and Swysh Inc. own the rights for prevention and treatment of certain infectious diseases. Both Pathway and Swysh have previously entered agreements with the Company to participate in and conduct clinical trials and other research activities related to possible Covid -19 treatments. This new agreement serves as an adjunct to those agreements by setting a course to fund and complete initial scientific trials activities on a general basis and in particular with respect to treatments for migraine and related health issues previously being developed by Pathway/Swysh. Specifically, this agreement is intended to address funding for pre-clinical toxicity trials required by Health Canada as precursors to more detailed clinical work to be completed in association with regional universities or similar institutions.